胸腺法新对晚期非小细胞肺癌化疗患者近远期疗效和预后的影响

Effects of Thymalfasin on Short-Term and Long-Term Outcomes and Prognosis in Patients Undergoing Chemotherapy for Advanced Non-Small-Cell Lung Cancer

目的探讨胸腺法新对晚期非小细胞肺癌(NSCLC)化疗患者近远期疗效和预后的影响。方法选取2012年1月至2014年6月收治的晚期NSCLC患者102例,按随机数字表法将其分为观察组与对照组,每组51例。对照组采用多西他赛+顺铂(Docetaxel Cisplatin,DP方案)化疗,观察组采用DP方案化疗+皮下注射胸腺法新,均连续化疗3个周期。比较2组近期疗效,生活质量改善率,治疗前后外周血T淋巴细胞亚群变化及随访1、2和3年生存率。结果观察组近期总有效率高于对照组(66.67%比47.06%,P<0.05),生活质量提高率高于对照组(66.67%比47.06%,P<0.05)。治疗后CD3^+、CD4^+、CD4^+/CD8^+比较:观察组高于治疗前(t=7.418、6.614、10.272,P<0.05),对照组低于治疗前(t=5.739、5.820、6.427,P<0.05);观察组高于对照组(t=13.378、14.204、13.764,P<0.05)。2组1年生存率比较差异无统计学意义(P>0.05);观察组2年和3年生存率高于对照组(P<0.05)。结论胸腺法新联合DP方案化疗对晚期NSCLC患者的近远期疗效确切,且可改善患者预后,提高其生存率。

Objective To investigate the effects of thymalfasin on short-term and long-term outcomes and prognosis in patients undergoing chemotherapy for advanced non-small-cell lung cancer(NSCLC).Methods A total 102 NSCLC patients admitted to our hospital from January 2012 to June 2014 were given 3 cycles of docetaxel+cisplatin(DP)chemotherapy alone(control group,n=51)or in combination with subcutaneous injection of thymalfasin(observation group,n=51).The short-term effect,improvement in quality of life,changes in peripheral blood T lymphocyte subsets and 1-,2-and 3-year survival rates were compared between the two groups.Results The total effective rate and improvement rate of quality of life in observation group were higher than those in control group(66.67%vs 47.06%and 66.67%vs 47.06%,respectively).After treatment,the CD3^+,CD4^+ and CD4^+/CD8^+ cells increased in observation group(t=7.418,6.614 and 10.272,respectively;P<0.05),but decreased in control group(t=5.739,5.820 and 6.427,respectively;P<0.05).Furthermore,the numbers of CD3^+,CD4^+,CD4^+/CD8^+ cells in observation group were higher than those in control group(t=13.378,14.204 and 13.764,respectively;P<0.05).There was no statistical difference in 1-year survival rate between the two groups(P>0.05).However,2-and 3-year survival rates in observation group were higher than those in control group(P<0.05).Conclusion The combination of thymalfasin and DP chemotherapy is associated with good short-term and long-term outcomes.The combined treatment can improve prognosis and increase survival rate in patients with advanced NSCLC.